According to, investors are lining up behind pharmaceutical firm Fibrogen on the weight of its investigational therapy for idiopathic pulmonary fibrosis, pamrevlumab.

FibroGen has convinced investors it has another potential blockbuster on its hands. Shares in the West Coast biotech shot up 60% after it posted top-line phase 2 pamrevlumab data that suggest the anti-connective tissue growth factor (CTGF) antibody can muscle in on a market fought over by Boehringer Ingelheim and Roche.

The centerpiece of the phase 2 idiopathic pulmonary fibrosis (IPF) data comes from a 103-patient trial in which participants took either pamrevlumab or placebo for 48 weeks. The study linked the drug to a 2.85 decline in forced vital capacity (FVC) % predicted, a measure of lung capacity. The average FVC % decline in the placebo cohort was 7.17, resulting in a statistically significant difference of 4.33 between the two arms